FDA to review tepotinib for use in metastatic NSCLC with METex14 Skipping Alterations

Tepotinib was granted Priority Review, and previously received breakthrough therapy designation. Evidence for use of this MET kinase inhibitor in non-small-cell lung cancer comes from the VISION study. A market authorisation application has yet to be filed in the EU.


Biospace Inc.